{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["40(7)"],"submitter":["Gonzalez-Robles C"],"funding":["Edmond J. Safra Philanthropic Foundation"],"pubmed_abstract":["<h4>Background</h4>There are currently no disease-modifying therapies (DMTs) registered for Parkinson's disease (PD). The Edmond J. Safra Accelerating Clinical Trials in Parkinson Disease (EJS ACT-PD) initiative will expedite clinical assessment of putative DMTs through a multi-arm multistage (MAMS) trial, testing several treatments against a common placebo arm and replacing unsuccessful therapies early.<h4>Objective</h4>The objective of this study was to describe the treatment selection process for the EJS ACT-PD clinical trial platform.<h4>Methods</h4>A Treatment Selection Working Group (TSWG) identified compounds using complementary strategies, such as literature search, related initiatives (Cure Parkinson's International Linked Clinical Trials [iLCT] initiative), and expert suggestions"],"journal":["Movement disorders : official journal of the Movement Disorder Society"],"pagination":["1307-1317"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12273612"],"repository":["biostudies-literature"],"pubmed_title":["Treatment Selection and Prioritization for the EJS ACT-PD MAMS Trial Platform."],"pmcid":["PMC12273612"],"pubmed_authors":["Bandmann O","Allison J","Mullin S","Dexter DT","Clarke CS","Jabbari E","Hockey K","Khengar R","Bale C","Petty R","Bakshi N","Martin K","Mortiboys H","McFarthing K","Barber TR","Duty S","Greaves V","Croucher R","Kapur N","Fletcher K","Matthews K","Matthews H","Stott S","Edwards M","Carroll CB","Wonnacott S","Gandhi S","Forbes J","Jewell A","Henderson E","Gros P","Scurfield P","Wyse RK","Ratcliffe N","Tofaris GK","Bartlett M","Miller L","Parry M","van Wamelen D","Korlipara P","Edwards A","Deeson E","Hu MT","Wong A","Athauda D","Wei L","Handley J","Black J","Jha A","Williams-Gray CH","Bhatia K","EJS ACT‐PD Consortium","Agarwal V","Millo SH","Hudson F","Drew C","Barker RA","Yarnall A","Navangul A","Chaudhuri KR","Bartolomeu-Pires S","Burnell M","Lambert C","Zetterberg H","Gonzalez-Robles C","Carpenter J","Mills G","Barker R","Dexter D","Barber T","Sammler E","Foltynie T","Weil RS","Breen D","Duffen J","Ellis-Doyle R","Silverdale M","Whone A","Stott SRW","Schrag A","Huxford B","Tofaris G","Batla A","Lawton M","Piccini P","Pushparatnam K","Schapira AH","Morris H","Noyce A","Counsell C","Siu C","Collins S","Schapira AHV","Zeissler ML","Rochester L","Ben-Shlomo Y","Ali S","Collins H"],"additional_accession":[]},"is_claimable":false,"name":"Treatment Selection and Prioritization for the EJS ACT-PD MAMS Trial Platform.","description":"<h4>Background</h4>There are currently no disease-modifying therapies (DMTs) registered for Parkinson's disease (PD). The Edmond J. Safra Accelerating Clinical Trials in Parkinson Disease (EJS ACT-PD) initiative will expedite clinical assessment of putative DMTs through a multi-arm multistage (MAMS) trial, testing several treatments against a common placebo arm and replacing unsuccessful therapies early.<h4>Objective</h4>The objective of this study was to describe the treatment selection process for the EJS ACT-PD clinical trial platform.<h4>Methods</h4>A Treatment Selection Working Group (TSWG) identified compounds using complementary strategies, such as literature search, related initiatives (Cure Parkinson's International Linked Clinical Trials [iLCT] initiative), and expert suggestions","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jul","modification":"2025-08-31T03:11:21.802Z","creation":"2025-08-31T03:05:14.714Z"},"accession":"S-EPMC12273612","cross_references":{"pubmed":["40249275"],"doi":["10.1002/mds.30190"]}}